Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Head and Neck Neoplasms 121Lung Neoplasms 119Glioblastoma 118Carcinoma, Non-Small-Cell Lung 118Breast Neoplasms 105Lymphoma 102Squamous Cell Carcinoma of Head and Neck 90Central Nervous System Neoplasms 83Prostatic Neoplasms 80Leukemia 77Pancreatic Neoplasms 67Gliosarcoma 66Rectal Neoplasms 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 63Esophageal Neoplasms 63Brain Neoplasms 59Lymphoma, Large B-Cell, Diffuse 56Lymphoma, Follicular 55Lymphoma, Non-Hodgkin 49Hodgkin Disease 48Burkitt Lymphoma 46Sarcoma 43Lymphoma, Large-Cell, Immunoblastic 42Leukemia, Lymphocytic, Chronic, B-Cell 42Myelodysplastic Syndromes 37Lymphoma, Mantle-Cell 36Glioma 36Neoplasms 34Astrocytoma 34Lymphoma, B-Cell, Marginal Zone 33

Interventions

nimotuzumab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal × Radiotherapy × Clear all
NCT02591784 2022-03-17

Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 2 Completed
42 enrolled
Gastrointestinal

Esophageal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡